class="blog wp-embed-responsive wp-theme-foxiz wp-child-theme-foxiz-child supp-body td-standard-pack personalized-all menu-ani-1 hover-ani-1 btn-ani-1 btn-transform-1 is-rm-1 lmeta-dot loader-1 dark-sw-1 mtax-1 is-hd-5 is-backtop none-m-backtop is-mstick is-smart-sticky"
PCOS: use in combination with myo-inositol at physiological 40:1 myo/DCI ratio. High-dose DCI alone may impair oocyte quality (Bevilacqua studies). Pregnancy: myo-inositol studied for gestational diabetes; DCI balance important. Drug interactions: insulin (additive hypoglycaemia).
Inositol stereoisomer preferentially studied for insulin sensitisation in PCOS. Works synergistically with myo-inositol in 40:1 ratio. Independent high-dose DCI may be counterproductive.
Acts on cellular signalling pathways relevant to the documented clinical indications. Contains bioactive compounds with enzyme-modulating, receptor-binding, or antioxidant properties studied in peer-reviewed literature.
| Population | Safety rating | Max safe dose |
|---|---|---|
| General | Possibly safe | — |
| Pregnancy | Possibly safe | — |
| Elderly | Possibly safe | — |
No peer-reviewed clinical trial data found for this ingredient.
Data by supplement.ge — Public Health Institute of Georgia (PHIG)